The US Food and Drug Administration (FDA) has approved Strides Pharma Science Ltd's triamcinolone acetonide ointment, which is used to treat various skin infections, the company said in a release on Friday. First movers for a generic product in the US usually get a six-month exclusivity period to market the product. The ointment will be manufactured at the company's flagship plant at Bengaluru, and will be marketed by the company's subsidiary Strides Pharma Inc in the US. The company has 102 cumulative generic drug filings with US FDA, of which 33 are pending approval. Share ViaTopics Strides Pharma

Source: Mint January 24, 2020 09:55 UTC